Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13555454 | 1.00 | RECQL (0.37) | RECQLICAM1ATMCYP19A1TAS2R46 | |
| SCHEMBL16687626 | 1.00 | RECQL (0.37) | RECQLICAM1ATMCYP19A1TAS2R46 | |
| SCHEMBL12002470 | 1.00 | RECQL (0.37) | RECQLICAM1ATMCYP19A1TAS2R46 | |
| SCHEMBL19830167 | 0.72 | PTPN1 (0.32) | PTPN1 | |
| SCHEMBL23007994 | 0.69 | ICAM1 (0.44) | RECQLICAM1ATMCYP19A1TAS2R46 | |
| SCHEMBL21475315 | 0.69 | ICAM1 (0.44) | RECQLICAM1ATMCYP19A1TAS2R46 | |
| SCHEMBL21475309 | 0.69 | ICAM1 (0.44) | RECQLICAM1ATMCYP19A1TAS2R46 | |
| SCHEMBL8513390 | 0.66 | PTGS2 (0.48) | RECQLCYP3A4TDP1 | |
| SCHEMBL13555455 | 0.66 | PTGS2 (0.48) | RECQLCYP3A4TDP1 | |
| SCHEMBL13555308 | 0.66 | PTGS2 (0.48) | RECQLCYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028550-A1 | USE OF ALBIFLORIN OR PHARMACEUTICALLY ACCEPTABLE SALT FOR PREVENTION AND/OR TREATMENT OF IRRITABLE BOWEL SYNDROME | ZHANG ZUOGUANG (CN) | 2018-02-01 | — | — | US | disclosed |
| US-9555055-B2 | Use of albiflorin and metabolites thereof | ZHANG ZUOGUANG (CN) | 2017-01-31 | — | — | US | disclosed |
| US-9023817-B2 | Use of albiflorin for anti-depression | ZHANG ZUOGUANG (CN) | 2015-05-05 | — | — | US | disclosed |
| US-20120270820-A1 | USE OF ALBIFLORIN FOR ANTI-DEPRESSION | ZHANG ZUOGUANG (CN) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028550-A1 | USE OF ALBIFLORIN OR PHARMACEUTICALLY ACCEPTABLE SALT FOR PREVENTION AND/OR TREATMENT OF IRRITABLE BOWEL SYNDROME | ALPI, ALB, SLC10A2 | RECQL 1242/4885ICAM1 3713/4885ATM 3331/4885 |
| US-20120270820-A1 | USE OF ALBIFLORIN FOR ANTI-DEPRESSION | GAP43, ALB, GRM5 | RECQL 646/4885ICAM1 4036/4885ATM 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.